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The hypocholesterolemic effect of isolated soybean proteins and fenofibrate in rats was
compared. Forty-five rats were divided into five groups: standard (STD; casein), high choles-
terol (HC; STD plus 1% cholesterol/0.5% cholic acid), HC + b-conglycinin, HC + glycinin and
HC + fenofibrate. The proteins and the drug were administered by gavage for 28 days. The
proteins decreased total cholesterol (TC) and triacylglycerol (TG) in the plasma of the rats
fed HC diet, to values very close to those fed on fenofibrate. High density lipoprotein cho-
lesterol (HDL-C) levels in the plasma were increased by the b-conglycinin, glycinin and
fenofibrate groups. The largest TC reduction in the liver was observed in the fenofibrate
group; in contrast, the b-conglycinin and glycinin groups exhibited reduced the levels of
hepatic TG and TC. Based on these data, it could be suggested that the oral daily adminis-
tration of isolated soybean proteins, in the range of 2.75% of the protein ingested daily, can
promote a reduction in TC and TG in the plasma of rats fed hypercholesterolemic diets.
Crown Copyright  2010 Published by Elsevier Ltd. All rights reserved.1. Introduction of hypercholesterolemia and/or tolerance to a pharmacolog-The growing importance of treating hyperlipidemia and
hypercholesterolemia with a diet-drug combination is well
recognized and increasingly diet therapy moves in this direc-
tion (Knopp, 1999; Poli et al., 2008). Thus, several studies
have highlighted the diet as an important element among
the possible forms of intervention aimed at reducing lipids
(cholesterol, LDL-C, TG) in the plasma (Poli et al., 2008;
Scarafoni, Magni, & Duranti, 2007). The inclusion of some
foods as dietary supplements takes into account the contextight  2010 Published by
t of Food and Nutrition,
1-902 Araraquara, SP, Br
.A. Neves).
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cholesterol; LDL/HDL, low
brate; FDA, Food and Drical intervention. Leguminous seeds are among the richest
food sources of protein for humans and animals nutrition.
In addition to the nutritional properties of their proteins,
the beneficial effects of dietary seeds on lipid metabolism
have been demonstrated in a variety of animal models and
humans (Scarafoni et al., 2007). In this respect, the soybean
stands out, since it contains higher protein content (35–
40%) than most other legumes. Several studies have shown
evidence that soybean proteins and not other compounds
present in the grain are responsible for its beneficial effectsElsevier Ltd. All rights reserved.
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Lichtenstein, & Lamarche, 2004; Duranti, 2006; Rho, Park,
Ahn, Shin, & Lee, 2007; Torres, Torre-Villalvazo, & Tovar,
2006; Wilson, Nicolosi, Kotyla, & Fleckinger, 2007) and scien-
tific data in support of this central role of soy protein have
led the American Food and Drug Administration (FDA) to
authorize a specific health recommendation to include 25 g
of soy protein a day in a diet low in saturated fat and choles-
terol, on the basis of a number of previous clinical observa-
tions ( FDA, 1999). Soybean protein, in the form of isolate,
concentrate and isolated protein fractions, has shown activ-
ity on cholesterol metabolism in studies in vitro and in vivo
(Scarafoni et al., 2007; Torres et al., 2006). A meta-analysis
published recently reported that soy protein, when partially
or fully substituted for dietary animal protein, induced a
decrease in plasma total and LDL-cholesterol and it was
observed that this reduction was greater in subjects with
established hypercholesterolemia and practically negligible
in those with baseline cholesterolemia (Reynolds, Chin, &
Lees, 2006; Sirtori, Ederini, & Arnoldi, 2007).
Storage globulins comprise two main constituents of the
protein in soybean seeds that can be differentiated by their
sedimentation coefficients, the 7S protein or b-conglycinin
and the 11S protein or glycinin. These constitute nearly 90%
of all the protein in the seed. While the 11S fraction has not
attracted much attention in the studies on lipid metabolism,
the 7S protein has been extensively studied in several exper-
imental designs, involving various animals, such as rats, nor-
mal and genetically obese mice and monkeys (Duranti et al.,
2004; Fukui et al., 2004). All of these studies show the 7S frac-
tion as the only protein source in the diet, but in a hypercho-
lesterolemic validated model, Lovati et al. (1992) had already
observed, and recently Duranti et al. (2004) confirmed that
the administration of a daily dose of the 7S fraction signifi-
cantly decreased plasma cholesterol and triacylglycerols in a
dose-dependent fashion. The former authors showed that
the 11S fraction had a much lower effect than the 7S, while
the latter demonstrated the key role played by the a 0 chain
on the cholesterolemic and triacylglycerolidemic levels, ow-
ing to the isolation of relatively large amounts of this subunit
from the 7S globulin. These authors suggested that peptides
produced in vivowould be the active elements in the observed
effects.
In the present study, the effects of a daily dose of the 7S
and 11S soybean protein fractions on total cholesterol (TC),
lipoproteins (LDL-C, HDL-C) and triacylglycerol (TG) levels in
the plasma were assayed, as well as TC and TG in the liver
of rats fed a hypercholesterolemic (HC) diet for 28 days. In
addition, the effects of fenofibrate, a hypolipidemic and hyp-
ocholesterolemic drug, were also studied in the same model.2. Methods and materials
2.1. Isolation and characterization of b-conglycinin (7S)
and glycinin (11S)
Soybean flour (60 mesh) was defatted with hexane (1:8, w/v)
flour to solvent ratio) by rocking at room temperature for
12 h followed by reextraction in the same solvent (1:6, w/v);evaporated to dryness at room temperature and used for pro-
tein extraction. Soybean fractions b-conglycinin and glycinin
were isolated following the method of Nagano, Hirotsuka,
Mori, Kohyama, and Nishinari (1992) with some modifica-
tions. Defatted soybean flour was extracted with water (1:15
w/v flour to water ratio) adjusted to pH 7.5. The soluble ex-
tract was centrifuged at 2000 g for 30 min. The supernatant
was treated with anhydrous sodium bisulphite (0.98 g/L) and
the pH adjusted to 6.4. The solution was stirred and stored
on an ice bath overnight, followed by centrifugation at 6500
g for 20 min. The insoluble fraction, containing 11S globulin,
was washed, centrifuged again under the same conditions,
suspended in distilled water, dialyzed overnight against dis-
tilled water in appropriate dialysis sacs (pore size of about
10 kDa) and lyophilized. The soluble fraction was treated with
0.25 mol/L NaCl and adjusted to pH 5.0 and, after 1 h, centri-
fuged at 9000 g for 30 min. The precipitate (7S or b-conglyci-
nin) was solubilized in 0.25 mol/L sodium phosphate buffer
(pH 7.0) and stored at 14 C. All steps were realized at 4 C.
All chemicals were of analytical purity.
Protein was determined by the method of Lowry,
Rosebrough, Farr, and Randall (1951), using bovine serum
albumin (BSA) as a standard. Electrophoresis of soybean total
protein, 7S-globulin and 11S-globulin was performed on 10 g/
100 g polyacrylamide gels containing 0.1% sodium dodecyl
sulfate (SDS), as described by Laemmli (1970), in a Mini Pro-
tean II cell (Bio-Rad, Hercules, CA,USA) (SDS–PAGE). About
10 lg of sample was loaded on each gel. The gels were stained
in Coomassie Brilliant Blue (R-250) and destained by diffusion
in methanol–acetic acid–water (1:1:8, v/v/v). Marker proteins
of known molecular weight (MW) were rabbit muscle phos-
phorylase b, bovine serum albumin, hen egg white albumin,
bovine carbonic anhydrase, soybean trypsin inhibitor and
hen egg white lysozyme. Gel images were digitalized and
analyzed by densitometry with an alpha Imager 6.0 scanner
(Alpha Innotech, San Leandro, CA, USA), to quantify the
bands and level of purity (data not shown). The content and
homogeneity of the isolated b-conglycinin and glycinin,
determined by SDS–PAGE and densitometric gel analysis,
showed that these were the main fractions, containing
92.2% and 91% protein, respectively. The gels showed the
characteristic bands of conglycinin (7S), due to the subunits
a, a 0, b, and glycinin (11S), with six subunit bands made up
of acidic and basic polypeptides. The procedure used to iso-
late 7S and 11S globulins did not cause changes in the sub-
units; this step was essential to obtain a purified protein
suitable for the in vivo studies (data not shown).
2.2. Animals, diets and experimental protocol
Forty-five male weanling Wistar rats, weighing 148 ± 12.3 g,
were obtained from the Central Laboratory for animals of
the Sa˜o Paulo State University (UNESP) at Botucatu. All proce-
dures were performed in accordance with the principles in
the Guide for the Care and Use of Laboratory Animals
(National Research Council, 1985) and animal maintenance
followed the guidelines of the Committee On Animal Experi-
ments of the University; these experiments were approved
by the Research Ethics Committee of the School of Pharma-
ceutical Sciences, Sa˜o Paulo State University (UNESP), under
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and fed standard laboratory rat chow (Purina). After this per-
iod, they were randomly divided into five groups (n = 9): a
standard group (STD) that received a normal casein-based
diet, following the recommendations of The American Insti-
tute of Nutrition (AIN-93) for maintenance (Reeves, Nielsen,
& Fahey, 1993), and four hypercholesterolemic groups (HC):
(1) control HC, (2) 7S globulin, 300 mg/kg/day (HC + 7S), (3)
11S globulin, 300 mg/kg/day (HC + 11S) and (4) fenofibrate,
30 mg/kg/day, (HC + FF). All HC groups were fed with a
AIN-93 diet, modified by adding of 1 g/100 g cholesterol, and
0.5 g/100 g cholic acid (Duranti et al., 2004; Nath, Wiener,
Harper, & Elvehjem, 1959), as described in Table 1.
Animals were individually housed in stainless steel
cages, with free access to food and water. The room tem-
perature was maintained at a constant 23 ± 2 C and relative
humidity of 60 ± 5%, with a 12–12 h light–dark cycle, lights
on at 6:00 a.m. The proteins (7S and 11S globulins) and
fenofibrate were administered daily by gavage at 9:00 and
14:00 h, in proportion to the body weight of the animals,
to the groups HC + 7S, HC + 11S and HC + FF; they were dis-
solved in saline and given at the rates of 300 and 30 mg/kg/
day, respectively. Vehicle alone was given to the HC group.
Body weight, food intake, fecal excretion and feeding effi-
ciency were measured every other day for comparative
analysis between groups during the 28 days of the experi-
ment. The feeding efficiency coefficient was calculated from
the ratio of weight gain/daily intake · 100. On the last day,
the animals were deprived of food for 12 h and euthanized
by guillotine. Blood was then collected in tubes containing
gel separator SST II (Vacutainer BD D, Franklin Lakes, NJ,
USA) and centrifuged at 1900 g for 15 min. The serum was
separated, stored at 24 C and used for biochemical analy-
sis. Retroperitoneal fat, liver and heart were removed,
washed immediately in cold saline, weighed; frozen andTable 1 – Composition (percent) of the diets and treatments of
STD HC
Ingredients
Caseinb 15 15
Starch 61.07 59.57
Sucrose 10 10
Soybean oil 4 4
Cellulose powder 5 5
Mineral mixturec 3.5 3.5
Vitamin mixturec 1 1
L-Cystine 0.18 0.18
Choline bitartrate 0.25 0.25
Cholesterold 0 1
Cholic acidb 0 0.5
Treatment
b-Conglycinin (mg/kg/day) – –
Fenofibrate
a STD = standard diet, AIN-93 composition; HC = hypercholesterolemic
HC + 7S = HC diet + b-conglycinin (300 mg/kg/day); HC + 11S = HC diet + gly
day).
b Sigma–Aldrich, Co., USA.
c PragSoluc¸o˜es, Co., Brazil.
d Reagen Co., USA.stored at 40 C for time less than a month for subsequent
comparative analysis.
2.3. Biochemical analysis in plasma and liver
To find out the effects of diets and treatment on the rat
groups, plasma total cholesterol (TC) was measured by the li-
quid cholesterol CHOD–PAP method described by Stockbridge,
Hardy, and Glueck (1989); serum high density lipoprotein
(HDL-C) was measured by HDL-C precipitation as described
by Assmann (1979); triacylglycerols (TG) were measured by
the liquid triglyceride GPO–PAP method, as described by
Annoni, Botasso, Ciaci, Donato, and Tripodi (1982). All analy-
sis were carried out by enzymatic colourimetric methods,
using commercially available reagent kits (Laborlab Co.,
Ribeira˜o Preto, Brazil). The non-HDL-cholesterol fraction
(non-HDL-C or LDL-C + VLDL-C) was calculated as the differ-
ence between the TC and HDL-C. The atherogenic index
(TC  HDL-C/HDL-C) was calculated as proposed by Liu et al.
(2006) and compared between groups. Hepatic-somatic and
visceral fat indexes were respectively calculated as follows:
liver weight/body weight · 100, and fat visceral weight/body
weight · 100, as described by Chen, Chiou, Suetsuna, Yang,
and Yang (2003). Liver lipids were extracted by the method
of Haug and Hostmark (1987). The liver TC and TG concentra-
tions were measured as described earlier for plasma analysis.
2.4. Statistical analyses
Data were analyzed by one-way analysis of variance (ANOVA)
and Student–Newman–Keuls multiple range tests, employing
SigmaStat 3.5 software (Dundas software, Germany, 1999).
All values are presented as mean ± standard error for nine
values per group. A differencewas considered statistically sig-
nificant when P < 0.05.the experimental groups.a
HC + 7S HC + 11S HC + FF
15 15 15
59.57 59.57 59.57
10 10 10
4 4 4
5 5 5
3.5 3.5 3.5
1 1 1
0.18 0.18 0.18
0.25 0.25 0.25
1 1 1
0.5 0.5 0.5
300.0 300.0 –
– – 30
diet: AIN-93 plus 1 g/100 g cholesterol and 0.5 g/100 g cholic acid;
cinin (300 mg/kg/day) and HC + FF = HC diet + fenofibrate (30 mg/kg/
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3.1. Parameters of the in vivo experiment
In this study, 7S and 11S isolated soybean globulins and fenof-
ibrate were given in single daily doses in an experimental
model described in methods. Table 2 shows the effects of dai-
ly administration of b-conglycinin, glycinin and fenofibrate on
the food consumption, weight gain, feeding efficiency ratio
and fecal excretion in rats fed the diets for 28 days. There
were no statistical differences (P > 0.05) in body weight gain
between groups during the experimental period (Table 2)
and also no significant (P > 0.05) alterations in the feeding effi-
ciency ratio or food intake between groups (Table 2).
TheHC group showed an increase of 24.2% and 21.1% in the
relative liver weight of rats and in the hepatosomatic index,
respectively, relative to the casein group (P < 0.01) (Table 3).
However, the rats treated with fenofibrate showed increases
of 55.8% and 63.6% in these values, respectively, relative to
the hypercholesterolemic group (P < 0.001). Although the
weight of the liver in the animals of the glycinin group were
lower than in the fenofibrate group, there was no statistical
difference; indeed, the hepatosomatic index for this group
was still 28.8% higher than for HC (P < 0.001). Meanwhile, noTable 2 – Body weight change, food intake and feeding efficien
diets.
STD HC
Initial body weight (g/rat) 195.23 ± 5.03 196.55 ± 4.63
Final body weight (g/rat) 287.77 ± 7.07 295.01 ± 5.43
Weight gain (g/rat/day) 3.31 ± 0.24 3.51 ± 0.32
Food intake (g/rat/day) 15.47 ± 0.27 16.74 ± 0.33
Fecal excretion (g/rat/day) 2.61c ± 0.08 3.59a ± 0.12
Feeding efficiency (%) 21.36 ± 1.67 21.01 ± 1.44
1 Values with different superscript letters in the same row differ significan
value is the mean ± SE (n = 9). STD = standard diet, AIN-93 composition; H
0.5 g/100 g cholic acid; HC + 7S = HC diet + b-conglycinin (300 mg/kg/day
diet + fenofibrate (30 mg/kg/day).
Table 3 – Tissue weights and ratios of rats after 28 days of fee
STD HC
Liver weight (g/rat) 10.90c ± 0.45 13.54b ±
Epididymal adipose tissue (g/rat) 5.05a ± 0.36 5.54a ±
Heart (g/rat) 1.08 ± 0.04 1.03 ± 0
Heart weight/body weight (g/100 g) 0.37 ± 0.01 0.34 ± 0
Hepatosomatic index2 3.79 ± 0.12 4.59c ± 0
Visceral somatic fat3 1.75a ± 0.11 1.89a ±
Atherogenic index4 1.02 ± 0.03 8.09a ±
1 Values with different superscript letters in the same row differ significan
value is the mean ± SE (n = 9). STD = standard diet, AIN-93 composition; H
0.5 g/100 g cholic acid; HC + 7S = HC diet + b-conglycinin (300 mg/kg/day
diet + fenofibrate (30 mg/kg/day).
2 Defined as liver weight/body weight · 100.
3 Defined as fat visceral weight/body weight · 100.
4 Defined as (TC  HDL-C)/HDL-C ratio.significant difference was found between these values in the
b-conglycinin group and the HC group (P > 0.05) (Table 3).
The ratios of fat to body weight and heart to body weight did
not vary significantly between the groups. However, animals
in the glycinin group showed a decrease of 34% and 32.5% in
visceral somatic fat and epididymal adipose tissue, respec-
tively, relative to other groups.
3.2. Plasma parameters
Oral administration of glycinin, b-conglycinin and fenofibrate
to hypercholesterolemic rats significantly reduced the levels
of TC and TG in the plasma of the animals relative to HC, by
the endof the 28-day treatment. In rats fed on thehypercholes-
terolemic diet (HC), the plasma and hepatic lipid levels were
significantly higher than in those given the standard diet
(STD) (P < 0.001) (Figs. 1–3). However, the daily administration
of b-conglycinin and glycinin to animals promoted an attenu-
ation of the effects of the HC diet, as also observedwith fenof-
ibrate. The animals that ingested b-conglycinin showed
reductions of 22.95% and 34.8% in the levels of TC and TG in
the plasma, respectively, relative to the HC group (P < 0.01),
while those that ingested glycinin showed reductions of 16%
and 16.3%, respectively (P < 0.05)(Fig. 1). On the other hand,cy ratio (FER) of rats after 28 days of feeding experimental
Dietary groups1
HC + 7S HC + 11S HC + FF
195.26 ± 3.64 194.55 ± 3.93 193.26 ± 3.64
300.64 ± 7.71 298.11 ± 5.30 281.14 ± 4.25
3,76 ± 0.29 3.71 ± 0.23 3.86 ± 0.29
16.25 ± 0.22 16.78 ± 0.33 15.35 ± 0.22
2.94b ± 0.09 3.38a ± 0.12 2.94b ± 0.09
23.05 ± 1.93 21.41 ± 1.07 23.21 ± 1.93
tly (P < .05) by the Student–Newman–Keuls multiple range tests. Each
C = hypercholesterolemic diet: AIN-93 plus 1 g/100 g cholesterol and
); HC + 11S = HC diet + glycinin (300 mg/kg/day) and HC + FF = HC
ding experimental diets.
Dietary groups1
HC + 7S HC + 11S HC + FF
0.36 13.55b ± 0.87 17.63a ± 0.28 21.10a ± 0.69
0.23 5.39a ± 0.46 3.74b ± 0.30 4.97a ± 0.24
.04 0.94 ± 0.03 1.06 ± 0.02 0.95 ± 0.03
.01 0.30 ± 0.02 0.35 ± 0.01 0.34 ± 0.01
.14 4.41c ± 0.20 5.91b ± 0.12 7.51a ± 0.27
0.10 1.79a ± 0.13 1.25 ± 0.10 1.76a ± 0.09
0.07 3.52c ± 0.11 5.04b ± 0.13 1.96d ± 0.12
tly (P < .05) by the Student–Newman–Keuls multiple range tests. Each
C = hypercholesterolemic diet: AIN-93 plus 1 g/100 g cholesterol and
); HC + 11S = HC diet + glycinin (300 mg/kg/day) and HC + FF = HC
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by 35.8% and 45.7%, respectively (P < 0.001). These latter data
indicate that the proteins b-conglycinin and glycinin produced
a considerable reduction of plasma TC and TG, compared to
fenofibrate (Fig. 1A/B) and there was no statistical difference
between the effects of the twoproteins onTC levels. In the case
of TG, the 7S protein group showed a remarkable fall reaching
the same level obtained with the drug.
The animals of the HC group showed a decrease of 43.6% in
HDL-C levels in the plasma, compared to the STD group
(P < 0.001), while those of rats fed b-conglycinin, glycinin and
fenofibrate were 55.5%, 20.0% and 95.5% higher, respectively,Fig. 1 – Plasma total cholesterol (A) and triglyceride (B) levels
of rats fed HC diet without and with oral daily doses of b-
conglycinin, glycinin or fenofibrate for 28 days. Values are
means ± SE for nine rats. Different letters indicate
differences between means. STD = standard diet: AIN-93
Composition; HC = hypercholesterolemic diet: AIN-93 plus
1 g/100 g cholesterol and 0.5 g/100 g cholic acid; HC+7S = HC
diet + b-conglycinin (300 mg/kg/day); HC+11S = HC diet +
glycinin (300 mg/kg/day) and HC+FF = HC diet + fenofibrate
(30 mg/kg/day).than the levels of the HC group; however, in the glycinin group,
these values were not significant at P < 0.05 (Fig. 2A). Fig. 2B
shows the effect of the diets on the non-HDL-C fraction. It
can be observed that this fraction was four times higher in
the HC group than in STD rats (P < 0.001). In contrast, the
administration of glycinin, b-conglycinin and fenofibrate
decreased this fraction by 20.7%, 33.2% and 53.1%, relative to
the HC group, respectively.
In the present study, the atherogenic index, a possible
indicator of a predisposition to heart diseases, was seven
times greater in the animals of the HC group than in STD
(P < 0.001); however, a decrease was observed for rats thatFig. 2 – Plasma HDL-C (A) and non-HDL-C (B) levels of rats
fed HC diet without and with oral daily doses of b-
conglycinin, glycinin or fenofibrate for 28 days. Values are
means ± SE for nine rats. Different letters indicate
differences between means. STD = standard diet: AIN-93
Composition; HC = hypercholesterolemic diet: AIN-93 plus
1 g/100 g cholesterol and 0.5 g/100 g cholic acid; HC+7S = HC
diet + b-conglycinin (300 mg/kg/day); HC+11S = HC diet +
glycinin (300 mg/kg/day) and HC+FF = HC diet + fenofibrate
(30 mg/kg/day).
Fig. 3 – Hepatic cholesterol (A) and triglycerides (B)
concentration of rats fed a HC diet without and whit oral
daily doses of b-conglycinin, glycinin or fenofibrate for 28
days. Values are means ± SE for nine rats. Different letters
indicate differences between means. STD = standard diet:
AIN-93 Composition; HC = hypercholesterolemic diet: AIN-
93 plus 1 g/100 g cholesterol and 0.5 g/100 g cholic acid;
HC+7S = HC diet + b-conglycinin (300 mg/kg/day);
HC+11S = HC diet + glycinin (300 mg/kg/day) and
HC+FF = HC diet + fenofibrate (30 mg/kg/day).
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the HC group (Table 3). Thus, b-conglycinin achieved 58%,
62.6% and 74.5%, and glycinin 21.7%, 39.0% and 49.7%, of
the performance of fenofibrate with respect to HDL-C, non-
HDL-C and atherogenic index in the animals, respectively.
3.3. Liver parameters
All the rat groups that received the hypercholesterolemic
diet showed significantly higher TC and TG levels in the liver
than those on the STD diet (P < 0.001), as shown in Fig. 3.However, relative to the HC rats, the b-conglycinin group
exhibited a reduction of 20.9% and 14.8% for hepatic TC
and TG, respectively; while the glycinin group showed no
change in TC levels and a decrease of 17.9% in hepatic TG
(P < 0.001). A greater reduction in TC level in the liver was
observed in the rats that had received fenofibrate: 32.1% low-
er than the HC group (P < 0.001); however, the levels of tria-
cylglycerols were 5.4% higher than in the HC group (P <
0.05).
4. Discussion
It has been demonstrated that fenofibrate can reduce food in-
take and body weight gain when administered at doses of
100 mg/day or during prolonged periods (Ferreira, Pereira,
Green, & Botion, 2006; Mancini et al., 2001), however, in our
experiment the dose of 30 mg/kg/day did not affect these vari-
ables. In addition, similar results have been described by
other authors, who used these soybean proteins as the only
protein source and observed no effect on the feeding effi-
ciency ratio and food intake after 28 days of experiment
(Fukui et al.,2002, 2004). In a study on humans, Kohono, Hirot-
suka, Kito, and Matsuzawa (2006) observed a significant
reduction of the adipose tissue weight and visceral fat weight
in 65 people of both sexes after 20 days of administration of
650 mg/day b-conglycinin in the form of candy, compared to
a placebo. The effects of b-conglycinin on TC and TG in the
plasma of rats confirm the observations made by other
authors (Duranti et al., 2004) using this experimental model.
However, our study represents the in vivo confirmation that
the administration of a daily dose of isolated glycinin is suffi-
cient to reduce plasma TC and TG in hypercholesterolemic
rats, as already described in vitro (Kwon et al., 2002; Pak,
Koo, Kasimova, & Kwon, 2005). Lovati et al. (1992) did not ob-
serve alterations in TG but only in TC levels in the plasma of
rats given the same two proteins in a similar experimental
model.
Investigations have shown that the relative low risk of cor-
onary heart disease (CHD) in Asian people is related to the use
of soy protein as a food source. The use of soy protein prod-
ucts at least four times per week decreases the risk of heart
disease by 22% (Herbert, Graziano, Chan, & Hennekens,
1997). The ratio of LDL-C to HDL-C is commonly used in order
to assess the risk of CHD, on the basis of evidence that an ele-
vated LDL-C concentration is atherogenic, whereas a greater
level of HDL-C is cardioprotective (Castelli et al., 1986).
Sawashita et al. (2006) reported that the antithrombotic effect
observed with a whole soy powder was due to inhibition of
the atherosclerotic process rather than to platelet inhibition.
Adams et al. (2004) found that b-conglycinin showed effects
on the inhibition of atherosclerosis in mice however; these
were not associated with the role of LDL receptors, and min-
imally related to the concentrations of plasma lipoproteins.
Rho et al. (2007) observed significant and progressive reduc-
tions of the atherogenic index in obese rats fed a diet contain-
ing black soy peptides at 2%, 6% and 10% of their energy
expenditure for 20 days, compared to a casein diet. In addi-
tion, Aoyama et al. (2001) found a 16% reduction for athero-
genic index in young rats and an increase of 7% in adult
rats that ingested b-conglycinin as a single protein source, rel-
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genic index, exhibited a decrease of 37.7%, 56.5% and 75.6%
for rats that ingested glycinin, b-conglycinin and fenofibrate,
respectively, relative to the hypercholesterolemic group (Table
3). These data indicate that both fenofibrate and the soybean
protein fractions diminish the cardiovascular risks in hyper-
cholesterolemic rats.
There is a lot of evidence to suggest that the concentra-
tions of triacylglycerols in the liver and plasma depend
mainly on the rate of hepatic lipogenesis (Brandsch, Shukla,
Hirche, Stangl, & Eder, 2006; Moriyama et al., 2004; Pak
et al., 2005). Raised TG levels in the liver and liver weight in
rats that ingested fenofibrate have also been reported by other
authors. Yamamoto, Fukuda, Zhang, and Sakai (1996) found a
reduced secretion of hepatic TG but not cholesterol in the li-
ver of rats that had ingested fenofibrate. Ferreira et al. (2006)
showed that fenofibrate treatment prevents hypertriglyceri-
demia, hypercholesterolemia and weight gain in rats by
reducing lipoprotein lipase activity in various tissues.
In a similar experiment, Lovati et al. (1992) reported a sig-
nificant fall in total TG concentration in the liver of the ani-
mals supplemented daily with 7S and 11S soybean proteins
for 14 days, compared to casein–cholesterol fed rats; however,
contrary to our results, the levels of cholesterol in the liver
were unaffected by the soybean proteins. This difference
could be related to the different concentrations of the pro-
teins used since those authors offered only 30 mg/day/animal
by gavage, or maybe the time of the experiment. Various
experimental studies in which b-conglycinin and glycinin
were used as the only protein source in the diet have demon-
strated their effects on lipid metabolism in several animal
models and in vitro. Thus, Aoyama et al. (2001) showed that
rats fed a diet containing b-conglycinin without phytate and
as the only source of protein presented a decrease of 34% in
TC, 49% in TG and an increase of 19% in HDL-C, compared
to rats fed a casein diet. Moriyama et al. (2004) found that
b-conglycinin reduced the plasma TG in normal and obese
rats, while glycinin did not alter its level. On the other hand,
Adams et al. (2004) observed that b-conglycinin and glycinin
in the diet had an effect on plasma TC levels that depended
on sex and type of transgenic mice; while both proteins raised
the TC levels in LDL-receptor-null male mice, they did not
affect the Apo-E-null animals. By contrast, glycinin and
b-conglycinin reduced the TC levels in the plasma of LDL-
receptor-null females by 37.0% and 40.6%, while they in-
creased the TC in Apo-E-null female mice by 43.6% and
11.2%, respectively. Recently, Adams, Anthony, Chen, and
Clarkson (2008) observed that in monkeys fed on a diet with
soy protein isolate, 7S and 11S soybean globulins, the TC lev-
els in the plasma showed a modest reduction of 5% for soy
isolate and the 11S fraction, while b-conglycinin increased
TC by 6.6%, relative to animals fed a casein/lactalbumin diet.
However, while these authors have used these fractions as
the only source of protein in the diet, in our experiment these
proteins represented only about 2.75% of the ingested total
protein/day/animal and yet caused increases of 56.8% and
21% in the plasma HDL-C for the respective proteins, while
the fenofibrate caused an increase of 97.8% in this lipoprotein.
Accordingly, our experiment confirms, in fact, the observa-
tions of Duranti et al. (2004) in rats on a hypocholesterolemicdiet, subjected to daily doses of 7S fraction and its a 0 chain;
however, in addition, we have recorded an increase of
HDL-C in the plasma and a fall in TC and TG levels in the liver
of the animals. The fibrates are effective triacylglycerol-
lowering drugs (Knopp, 1999) and our results show that the
administration of the isolated fractions had a significant
effect on TG and TC levels in hypercholesterolemic rats, com-
parable to fenofibrate.
Although the mechanisms of the cholesterol-lowering ef-
fects of soybean proteins are not yet clear, it is important to
raise the hypothesize that due to their large molecular size,
it is likely that the effects observed are not due to the intact
proteins, but certainly to peptides derived from them by gas-
trointestinal digestion, which, after absorption and transport
to the liver, could modulate the homeostasis of cholesterol, as
already discussed by other authors for soybean globulins
(Kwon et al., 2002; Mochizuki et al., 2009; Pak et al., 2005;
Yamamoto et al., 1996). Other studies suggest that the reduc-
tion of plasma cholesterol might be a consequence of an
interaction between these peptides and cholesterol, or its
metabolites, neutral sterols and bile salts, which promotes
its excretion (Iwami, Sakakibara, & Ibuki, 1986; Kohono
et al., 2006; Pak et al., 2005).
Lovati et al. (1996, 2000) have described a significant in-
crease in the expression of LDL-receptors in vitro after expo-
sure of HepG2 cells to the 7S fraction and the a’ subunit.
This increase in LDL-receptor expression may contribute to
the observed decrease in ApoB-100 secretion, since LDL-
receptor causes a post-translational degradation of ApoB-
100 and thereby reduces VLDL-particle secretion, as observed
by Mochizuki et al. (2009). Actually, these authors showed that
peptides from highly purified b-conglycinin decreased the
synthesis of TG and secretion of lipoproteins containing
ApoB-100 in HepG-2 cells. Moreover, using the same experi-
mental model, we found that the glycinin fraction had an ef-
fect similar to that of b-conglycinin on TC, TG and HDL-C in
the plasma of the animals, though with less intensity. The
present finding that the 11S fraction also has lipid-lowering
effects are in accord with previous observations in studies
in vitro and in vivo with diverse animals (Adams et al., 2008;
Kwon et al., 2002; Lovati et al., 1992; Moriyama et al., 2004;
Pak et al., 2005; Yoshikawa, Yamamoto, & Takenaka, 1999).
Pak et al. (2005) showed that peptides from the pepsin hydro-
lysate of glycinin exhibited in vitro hypocholesterolemic activ-
ity. On the other hand, Kwon et al. (2002) isolated three
different peptides from glycinin hydrolyzed by trypsin and
also found a hypocholesterolemic effect in vitro. The authors
also observed a 30% decrease in TC in the serum of mice
fed the glycinin peptides, while cholestyramine (bile acid
binding activity) and lovastatin (HMG CoA reductase inhibi-
tor) caused reductions of 29% and 32%, respectively.
Despite many studies in animals and in vitromodels, as al-
ready cited, the mechanisms of the reduction in cholesterol
levels by ingestion of soy protein are still far from clear
and, although advances have been made, controversy re-
mains (Adams et al., 2008; Scarafoni et al., 2007; Torres
et al., 2006). The data of the present study indicate that the
hypocholesterolemic effects of the soybean protein are re-
lated to both the b-conglycinin and glycinin fractions, and
suggest that biologically active peptides produced from by
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ulating cholesterol and triacylglycerol homeostasis.
In conclusion, our results show that oral ingestion of
b-conglycinin and glycinin at around 2.75% of the daily total
protein ingested, promoted the reduction of TC, LDL-C and
TG in the plasma and an increase in HDL-C; besides this, they
induced a small but significant decrease in TC and TG levels in
the liver, as well as in the atherogenic index, in rats fed a
hypercholesterolemic diet. Interestingly, the data show that
the hypocholesterolemic and hypolipidemic effects of the pro-
teins are comparable to those observedwith the fenofibrate in
the same experimental model. Studies are in progress to iden-
tify the effects of these proteins alone and/or combined with
other hypocholesterolemic drugs, such as the statins.
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